RIGEL PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-78.0M | $-69.2M | $-51.5M | $-90.9M | $-89.0M | $-98.8M | $-86.0M | $37.9M |
| Depreciation & Amortization | $465.0K | $941.0K | $1.4M | $2.4M | $2.6M | $2.4M | $2.0M | $1.3M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.0M | $7.3M | $7.4M | $9.8M | $7.2M | $12.6M | $13.2M | $16.4M |
| Net Cash from Operating Activities | $-77.6M | $-75.9M | $-23.4M | $-69.8M | $-86.1M | $-85.2M | $-69.4M | $46.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $164.0K | $804.0K | $546.0K | $413.0K | $1.2M | $3.4M | $2.3M | $3.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-19.5M | $24.9M | $44.6M | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $117.7M | $25.2M | $7.1M | — | — | — | — | — |
| Net Change in Cash | $20.7M | $-25.8M | $28.3M | — | — | — | — | — |
| Free Cash Flow | $-77.7M | $-76.7M | $-24.0M | $-70.2M | $-87.3M | $-88.6M | $-71.7M | $43.2M |